~," In a pilot study, two groups of patients with malignant glioma underwent sequential neuropsychological evaluations after successful tumor treatment. Group 1 included nine patients treated from 1981 to 1985; all patients received irradiation and eight underwent chemotherapy. The baseline neuropsychological assessment was performed 1 to 63 months after tumor diagnosis, with follow-up evaluations at irregular intervals over the next 3 to 7 years. Six patients in Group 1 exhibited impairment on most measures at baseline; subsequently, two patients developed profound cognitive impairment. Initially, three patients functioned in the average range on most tasks; thereafter, two deteriorated on one measure each. Group 2 was ascertained prospectively and included 16 patients treated from 1985 to 1987, all of whom received irradiation and chemotherapy. The first evaluation was performed 18 months after diagnosis, then every 6 months for 2 years, and then yearly. Compared to a control group, those in Group 2 had significant cognitive impairment at baseline. Cognitive performance did not change over the next 12 months in 10 patients who remained free of tumor, but within 2 years of baseline testing, deterioration on specific tasks was evident in two of seven disease-free survivors. When last tested, five of six disease-free survivors had deteriorated on one or more measures. Unlike Group 1, severe global cognitive impairment was not seen, perhaps because Group 2 was followed for a shorter time. Verbal and nonverbal composite scores derived from intelligence quotient (IQ) tests showed less impairment at baseline than did other measures and were more likely to remain stable subsequently. Verbal memory and sustained attention were the most impaired at baseline, and verbal learning and flexibility in thinking showed the greatest tendency to decline over time.
~," In a pilot study, two groups of patients with malignant glioma underwent sequential neuropsychological evaluations after successful tumor treatment. Group 1 included nine patients treated from 1981 to 1985; all patients received irradiation and eight underwent chemotherapy. The baseline neuropsychological assessment was performed 1 to 63 months after tumor diagnosis, with follow-up evaluations at irregular intervals over the next 3 to 7 years. Six patients in Group 1 exhibited impairment on most measures at baseline; subsequently, two patients developed profound cognitive impairment. Initially, three patients functioned in the average range on most tasks; thereafter, two deteriorated on one measure each. Group 2 was ascertained prospectively and included 16 patients treated from 1985 to 1987, all of whom received irradiation and chemotherapy. The first evaluation was performed 18 months after diagnosis, then every 6 months for 2 years, and then yearly. Compared to a control group, those in Group 2 had significant cognitive impairment at baseline. Cognitive performance did not change over the next 12 months in 10 patients who remained free of tumor, but within 2 years of baseline testing, deterioration on specific tasks was evident in two of seven disease-free survivors. When last tested, five of six disease-free survivors had deteriorated on one or more measures. Unlike Group 1, severe global cognitive impairment was not seen, perhaps because Group 2 was followed for a shorter time. Verbal and nonverbal composite scores derived from intelligence quotient (IQ) tests showed less impairment at baseline than did other measures and were more likely to remain stable subsequently. Verbal memory and sustained attention were the most impaired at baseline, and verbal learning and flexibility in thinking showed the greatest tendency to decline over time.
Cognitive functioning in survivors of high-grade glioma is best measured and monitored by tests that probe a broader spectrum of abilities than IQ. Neuropsychological measures used in this analysis lacked sensitivity at the lower end of the impaired range. Future studies should use tests better able to discern cognitive differences at low performance levels. Based on this experience, the authors conclude that most long-term survivors of high-grade glioma will have significant cognitive difficulties, usually evident by the first assessment; some patients will develop profound impairment years later, and few are capable of fully independent living.
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cognitive function 9 malignant glioma 9 radiation therapy 9 chemotherapy 9 outcome O ER the past 25 years, aggressive multimodality treatment of high-grade gliomas has resulted in larger numbers of long-term survivors/5 With successful treatment has come the realization that many survivors have significant cognitive difficulties. TM Increasingly, patients and physicians are asking whether intellectual deterioration is an inevitable consequence of successful treatment. Several prospective longitudinal studies of children with medulloblastoma and other brain tumors have documented low intelligence quotients (IQ's) and learning difficulties in successfully treated patients, 7,s,2~ and in some leukemic children prophylactic cranial irradiation and intrathecal chemotherapy are followed by late cognitive difficulties? ,5,9,~7.19 For adults with malignant glioma, there is relatively little information on the effects of surgery, irradiation, and chemotherapy on higher brain functions. The available data suggest diffuse cognitive decline and problem-solving difficulties in a significant proportion of long-term survivors.~~ Most studies have been retrospective or unsystematic, with few attempts to document specifically and prospectively the incidence, time course, and extent of cognitive problems. This pilot project, designed primarily to address methodological issues, describes the results of sequential neuropsychological testing in two groups of patients with successfully treated malignant glioma.
Clinical Material and Methods

Patient Population
Group 1 included nine English-speaking patients (four men and five women), aged 22 to 58 years, with unifocal biopsy-proven malignant glioma. A tumor had been diagnosed in these patients between 1981 and 1985. They were tumor-free as demonstrated on computerized tomography (CT) at the end of aggressive treatment and remained so for an extended period. Each patient underwent repeated neuropsychological evaluations beginning 1 to 63 months after diagnosis (mean _+ standard deviation: 33.4 + 20.6 months). The interval between assessments varied considerably but each patient had at least four assessments (maximum nine); the last assessment was made between 62 and 108 months after diagnosis. Testing included measures of intellectual function, attention, memory, learning, information processing, and flexibility in thinking. Most, but not all, measures were examined at baseline. Based on demographic data, 2 their premorbid IQ was estimated to be in the mid-average range (mean 104 + 7). Histological tumor type, tumor location, extent of resection, and postoperative treatment are summarized in Table 1 .
Group 2 was ascertained and evaluated prospectively. Between May 1, 1987, and April 30, 1989, 16 English-speaking nonaphasic patients (eight men and eight women), aged 18 to 63 years, with unifocal biopsy-proven malignant glioma in whom CT scans did not demonstrate tumor following surgery, irradiation, and adjuvant chemotherapy participated in a longitudinal study of cognitive performance. Those patients with persistent tumor after treatment (unlikely to be long-term survivors) were excluded. Seventeen patients met all the eligibility criteria, and 16 agreed to enter the study. Three participants were taking anticonvulsant agents throughout the test period. The educational achievement in Group 2 patients ranged from an elementary school diploma to a baccalaureate degree (mean 13.1 _+ 3.0 years of schooling). Comprehensive testing of their intellectual function, attention, memory, visual, visuospatial, and constructional skills, motor and sensory functions, language ability, and flexibility in thinking was scheduled at 6-month intervals over a 2-year period (the duration of the study). Thereafter, disease-free survivors were evaluated at yearly intervals for an additional 2 to 3 years. The baseline assessment was performed at the end of treatment, approximately 1 89 years after diagnosis (mean 17.5 _+ 4.3 months). An interview assessing physical complaints, mood, and general functioning was conducted during each test session, and a neurological examination and CT were performed within 2 weeks of each assessment.
Patients did not have neuropsychological testing until the end of tumor treatment but, based on demographic data, their mean premorbid IQ was estimated to be 105 _+ 7.8), well within the average range of 90 to 109. Histological tumor type, tumor location, extent of resection, and postoperative treatment are summarized in Table 2 . Nine patients did not complete the study (all five test sessions). Tumor recurred intracerebrally in seven and in the spinal cord in one; one patient withdrew from the study (Table 3) . To compare study patients with their unaffected peers, we tested a control group of patient spouses and hospital volunteers matched for age and educational achievement. The 16 control subjects (four men and 12 women) had a mean age of 36.4 _+ 11.2 years and 13.3 _+ 3.0 years of formal education.
Statistical Analysis
Eight measures evaluating different aspects of cognitive function (Table 4) were analyzed for Group 1, Group 2, and the control group. For Group 1, variability in timing of the baseline assessment and intertest intervals precluded meaningful statistical evaluation; instead, a descriptive account of these patients is pre- sented. For Group 2, the Mann-Whitney U-test was used to compare baseline cognitive performance with that of the control group. The Wilcoxon matched-pairs signed-rank test was used to compare baseline results with performance scores 1 year later for those who remained disease-free. Each patient served as his or her own control. Subsequent changes in cognitive performance could not be evaluated statistically because so few patients were disease-free at the 2-year mark.
Results
Cognitive Function
Cognitive performance over time for the nine patients in Group 1 is summarized in Table 5 . Cases 2, 3, and 6 to 9 functioned in the impaired range or were at the lowest level measurable ("floor level")* on most measures at baseline. Subsequently Cases 6 and 7 deteriorated on most measures and became virtually untestable, while the others remained relatively stable. Two patients (Cases 2 and 9) became increasingly unable to function at home, but this apparent deterioration was not reflected in their test scores. Cases 1 and 4 * The measures used in this study did not detect decline below floor levels. Tables 5 and 8. functioned in the average range on some or most measures at baseline; subsequently, both deteriorated on one measure but remained stable otherwise. Case 5, the only patient who did not have adjuvant chemotherapy, performed in the average range on all but one measure at baseline and showed no evidence of cognitive decline on subsequent assessments. Two patients died, Case 2 of metastatic adenocarcinoma (primary site unknown) and Case 6 of pneumonia; neither patient had evidence at autopsy of residual anaplastic oligodendro- Table 4 for definitions of cognitive function. Avg = average range; Imp = impaired range; floor = floor levei; NG = not given; NC/S = no change/stable. glioma. Seven patients are alive: two (Cases 3 and 8) have recurrent tumor and are incapable of independent living; two (Cases 7 and 9) are tumor-free but require assistance with activities of daily living; two (Cases 1 and 4) are disease-free and living independently but not working; and one (Case 5) is tumor-free, managing a household, and working parttime.
Group 2 patients were significantly impaired on all measures at baseline compared to the control group (Table 6) . Moreover, each patient in Group 2 was impaired or at floor level on some or all measures at baseline. These impairments were probably the result of cognitive deterioration because their premorbid intellectual functioning was estimated to be in the midaverage range. For the 10 patients in Group 2 who remained disease-free over the ensuing 12 months (Cases 1, 3 to 7, 10, 11, 14, and 16, Table 2 ), cognitive performance did not decline further during that year (Table  7) but, unrelated to tumor recurrence, declined thereafter in some (Table 8 ). Cases 4, 5, 10, 14, and 16 were stable or improved at the 2-year mark; however, one (Case 3) had deteriorated in nonverbal memory, verbal learning, and sustained attention, and another (Case 7) had deteriorated in sustained attention and flexibility in thinking. One patient (Case 5) died of recurrent tumor shortly after the 2-year mark. When last tested, one patient (Case 4) had declined in verbal learning and flexibility in thinking, one patient (Case 14) had declined in verbal leaming, one patient (Case 3) had declined in the composite nonverbal measure, verbal learning, sustained attention, and information processing, and one patient (Case 7) had declined in information processing (Table 8) . Scores for one patient (Case 10) fluctuated considerably, but at the last assessment verbal learning was severely impaired. One patient (Case 4) is alive with recurrent tumor and five patients (Cases 3, 7, 10, 14, and 16) are alive with no clinical or radiological evidence of recurrence; none is capable of fully independent living.
Cognitive Function Comparison
For both Groups 1 and 2, verbal and nonverbal composite scores derived from IQ tests were generally less impaired at baseline than other measures of cognitive function and were more likely than the others to remain stable over time. Verbal memory and sustained attention were often the most impaired at baseline, and verbal learning and flexibility in thinking often showed the greatest tendency to decline over time. Although some patients improved on some measures, there was no overall or measure-specific improvement on successive assessments as one might see with a practice (n < 6).
small for statistical comparison effect. There was no relationship between age at diagnosis and the degree or pattern of cognitive disturbance at baseline, or subsequently. For Group 2, mood remained relatively stable over time and generally within normal limits.
Tumor Type and Location
Combining Groups 1 and 2, there were four left frontal tumors, four right frontal, four left parietal, four right parietal, one left temporal, six right temporal, one left occipital, and one right occipital. Although there were too few patients in this study to confidently analyze cognitive difficulties in relation to tumor location, the most incapacitating deficits were found in patients with right parietal tumors and the least in those with right temporal ones. In many patients the extent of cognitive impairment was more widespread than expected, given the "localized" appearance of the tumor on CT scans.
Discussion
Several studies of adults with malignant gliomas have revealed cognitive decline over time in the absence of tumor recurrence. Maire, et al., ~ noted that deterioration occurred more than 30 months after radiation treatment and was more likely in older patients, and Hochberg and Slotnick ~~ observed progressive global and measure-specific cognitive impairment 1 year after surgery and irradiation. Imperato and colleagues 1: analyzed a series of patients who were treated aggressively at diagnosis and lived much longer than average, noting that most long-term survivors were cognitively impaired and functioned at a low level years later. Trojanowski, et al., ~7 in a systematic short-term prospective study of cognitive function, found pre-and postoperative impairment that improved over the following 6 months and then stabilized for 18 months. In addition, Lee, et al., t-~ reported impaired cognitive functioning and nonverbal memory 5 years after inadvertent brain irradiation in patients with nasopharyngeal carcinoma. In contrast, a recent study of memory difficulties alone by Kleinberg, et al.] 4 using subjective reports, indicated no such decline in cognitive functioning 3 89 years (median) after completion of cranial irradiation.
Our observations, based on an analysis of two groups of patients (the first a retrospective case series and the second a cohort ascertained and evaluated prospectively), support the former claim that cognitive difficulties are evident in long-term survivors of high-grade glioma. Very few patients with malignant glioma treated at this center in the early-to-middle 1980's are tumor-free and capable of fully independent living, and only one patient (Case 5 in Group 1) has reasonably normal cognitive function. Eight of the nine patients in Group 1 were cognitively impaired in one respect or another when first tested; two deteriorated subsequently in a severe and global fashion. Patients in Group 2 showed varying degrees of cognitive impairment at baseline, and five long-term survivors in this group deteriorated further over time. Tumor regrowth did not explain delayed cognitive decline in either group, but two patients in each had late recurrences. Late recurrences and the high rate of attrilion due to tumor regrowth in Group 2 emphasize how difficult it is to eliminate these cancers and to study treatmentrelated late effects.
The majority of tumor-free patients were cognitively impaired at the conclusion of aggressive anticancer treatment. Such early cognitive difficulties were almost certainly the result of multiple factors including, in addition to irradiation and chemotherapy, the disease itself and the effects of aggressive surgery. The relative contribution of disease and surgery to early impairment can be explored in future trials of conducting detailed neuropsychological evaluations before and after surgery and prior to radiation therapy and chemotherapy.
Progressive cognitive deterioration was observed in some disease-free long-term survivors. Damage to normal tissue by radiation treatment undoubtedly contributed to the decline. All patients in Group 1 received either whole-brain, whole-brain plus tumor boost, or large partial-brain irradiation. Several patients were treated unconventionally using larger fractional doses. All patients in Group 2 had standard whole-brain radiotherapy plus a tumor boost. Severe cognitive decline, akin to the dementia of advanced Alzheimer's disease, was observed in Group 1 but not in Group 2. Whether such profound deterioration is the result of the atypical radiation therapy prescribed for some patients in Group 1 or a late phenomenon that may yet befall those in Group 2 remains to be seen. Patients in Group 1 were last tested longer after diagnosis than those in Group 2 (62 to 108 months vs. 45 to 74 months). Progressive cognitive difficulties may be less common now that local radiation therapy has replaced whole-brain treatment, but this too remains to he seen. Chemotherapy may have played a role in delayed cognitive decline. Eight of nine patients in Group 1 and all 16 patients in Group 2 received adjuvant chemotherapy. The relative contributions of radiotherapy and chemotherapy to late deterioration are inextricable in this series of cases.
This pilot project was also very instructive from a methodological viewpoint. We observed, for example, that many of the standard neuropsychological tests lacked sensitivity at the lower end of the impaired range such that cognitive decline below floor levels could not be demonstrated in some patients judged to have deteriorated on clinical grounds. This was particularly true for two patients (Cases 2 and 9) in Group 1; both were impaired at baseline and remained stable on subsequent neuropsychological assessments but became increasingly unable to function at home. Future studies must address this issue by developing or choosing tests that are better able to discern cognitive dif-fcrences at low performance levels. We discovered that verbal and nonverbal composite scores, measures of cognitive functioning derived from IQ tests, were less indicative of the kinds of difficulties thai occurred in these patients, suggesting that IQ testing alone may not be the best method of measuring and monitoring cognitive function in survivors of high-grade glioma. Last, we learned that hundreds, perhaps thousands, of patients will need to be tested at diagnosis in order to yield sufficient numbers of disease-free long-term survivors to enable investigators to thoroughly examine the spectrum of delayed treatment-related toxic effects and their relationship to such variables as age, histology, and tumor size and location.
Treatment-related cognitive impairment, and the poor quality of life that results, is a relatively uncommon problem and may become even less common now that radiation therapy for malignant glioma is more focal. It is distressing to think that serious compromise of cognitive functioning and loss of independence may be the usual outcomes when aggressive therapy, as currently prescribed for malignant glioma, successfully controls the tumor. Cognitive impairment that results from treatment may become a significant medical and social problem when predictable effective therapies for these cancers finally emerge. The neurotoxic effects of radiation treatment and chemotherapy need further study in larger groups of patients. This will require multicenter participation, prospective evaluation, new methodologies, a long-term commitment to neuropsychological and quality of life assessments in braintumor patients, and a major commitment of resources to this endeavor.
